There is little information about the serologic survey for control of hepatitis C by using third-generation assays among chronic haemodialysis (HD) patients, and no analysis of costs has been made to this end.
A serologic survey for control of hepatitis C was performed in 190 HD patients attending a single dialysis unit, using second-and third-generation assays.
Costs of both serologic surveys were calculated.
Anti-HCV prevalence tested by third-generation assays increased from 25% (48/190) to 28% (53/190) compared to second-generation testing ; 56% (9/16) of patients showing uncertain findings by second-generation tests gave unequivocal results by third-generation assays ; median duration of HD treatment and raised aminotransferase levels were positively associated (P=0.004 and P=0.012, respectively) with anti-HCV detected by third-generation assays.
The serologic survey for control of hepatitis C in HD patients at our centre was slightly more expensive by third-generation assays compared to second-generation testing (US$ 18 866 vs US$17 200 per year).
In summary, the use of third-generation tests largely clarified the uncertain results of second-generation tests ; new additional positive patients were detected by third-generation assays compared to second-generation testing.
Third-generation assays showed the association of duration of HD treatment and raised aminotransferase levels with anti-HCV antibody, as previously found by first-and second-generation assays. (...)
Mots-clés Pascal : Hémodialyse, Complication, Hépatite virale C, Virose, Infection, Diagnostic, Exploration virologique, Sérologie, Examen laboratoire, Technique, Coût, Etude comparative, Homme, Epuration extrarénale, Appareil digestif pathologie, Foie pathologie, Economie santé
Mots-clés Pascal anglais : Hemodialysis, Complication, Viral hepatitis C, Viral disease, Infection, Diagnosis, Virological exploration, Serology, Laboratory investigations, Technique, Costs, Comparative study, Human, Extrarenal dialysis, Digestive diseases, Hepatic disease, Health economy
Notice produite par :
Inist-CNRS - Institut de l'Information Scientifique et Technique
Cote : 97-0177748
Code Inist : 002B24O06. Création : 21/05/1997.